LivaNova PLC (LIVN)
| Market Cap | 3.96B |
| Revenue (ttm) | 934.24M |
| Net Income (ttm) | -345.01M |
| Shares Out | 48.66M |
| EPS (ttm) | -7.10 |
| PE Ratio | n/a |
| Forward PE | 77.52 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $81.44 |
| Previous Close | $81.34 |
| Change ($) | 0.10 |
| Change (%) | 0.12% |
| Day's Open | 80.99 |
| Day's Range | 80.10 - 81.67 |
| Day's Volume | 68,607 |
| 52-Week Range | 41.07 - 83.61 |
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC will host a conference call to discuss its first quarter 2021 results on Wednesday, April 28, 2021 at 12 p.m. London time (7 a.m. EDT).
LivaNova (LIVN) delivered earnings and revenue surprises of 7.58% and -0.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of LivaNova (NASDAQ:LIVN) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share fell 29.00% over the past year to $0.71, which beat the estimate of $0.66.
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC today reported results for the quarter and full-year ended December 31, 2020.
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC will host a conference call to discuss its fourth quarter and full-year 2020 results on Feb. 24, 2021 at 1 p.m. London (8 a.m. EST).
LivaNova has upside levers in place to drive top-line growth over the coming periods, with a sequential growth pattern from Q2 to Q3. The company recently sold its heart valves arm, removing this underp...
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC today announced a series of enhancements to the Company's governance.
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova announced it will host “Updates and Advances in Neuromodulation,” a satellite symposium at AES2020 on Dec. 6, featuring leading clinicians.
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova and Gyrus have entered into an agreement whereby entities funded and controlled by Gyrus will acquire the LivaNova heart valve business.
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC announced CEO Damien McDonald will participate in discussions at the Berenberg European Conference 2020 on December 2.
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova announced CEO Damien McDonald will participate in discussions at the Piper Sandler 32nd Annual Virtual Healthcare Conference Nov. 30-Dec. 3.
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova today announced Damien McDonald, CEO, will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17 at 10:40 a.m. ET.
Shares of LivaNova (NASDAQ:LIVN) were unchanged after the company reported Q3 results.
LivaNova (LIVN) delivered earnings and revenue surprises of 80.95% and 8.29%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended Sept. 30, 2020.
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC today confirmed receipt of a letter from PrimeStone Capital LLP to its Board of Directors and issued a statement.
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova presented Perceval and Perceval Plus data at the 34th Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS).
LONDON--(BUSINESS WIRE)---- $LIVN--LivaNova PLC will host a conference call to discuss its third quarter 2020 results on Thursday, October 29, 2020 at 12 p.m. London (8 a.m. EDT).
LivaNova (LIVN) delivered earnings and revenue surprises of 50.00% and 6.10%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of LivaNova (NASDAQ:LIVN) were unchanged after the company reported Q2 results.
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova PLC (LIVN) CEO Damien McDonald on Q1 2020 Results - Earnings Call Transcript
Shares of LivaNova (NASDAQ:LIVN) were unchanged at $56.37 after the company reported Q1 results.
LivaNova (LIVN) delivered earnings and revenue surprises of -2.94% and 3.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) delivered earnings and revenue surprises of 5.26% and -1.54%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) delivered earnings and revenue surprises of 16.67% and -1.55%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) is aiming to reach out to more patients, with improved enrollment program.
LivaNova (LIVN) delivered earnings and revenue surprises of 2.94% and 1.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Solid growth in emerging markets is expected to be an added positive this earnings season.
LivaNova PLC (LIVN) CEO Damien McDonald on Q1 2019 Results - Earnings Call Transcript
These stocks lost ground even as the broader market posted solid gains.
The medical-device company posted tepid preliminary first-quarter revenue.
About LIVN
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve r... [Read more...]
| Industry Medical Devices | IPO Date Feb 10, 1993 |
| CEO Damien McDonald | Employees 4,000 |
| Stock Exchange NASDAQ | Ticker Symbol LIVN |
Financial Performance
In 2020, LivaNova's revenue was $934.24 million, a decrease of -13.83% compared to the previous year's $1.08 billion. Losses were -$345.01 million, 122.3% more than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for LivaNova stock is "Buy." The 12-month stock price forecast is 85.17, which is an increase of 4.58% from the latest price.